Pain Therapeutics (PTIE) and Its Competitors Head-To-Head Review
Pain Therapeutics (NASDAQ: PTIE) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Pain Therapeutics to similar companies based on the strength of its risk, analyst recommendations, dividends, earnings, valuation, profitability and institutional ownership.
Insider & Institutional Ownership
36.2% of Pain Therapeutics shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 32.7% of Pain Therapeutics shares are held by company insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares Pain Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Pain Therapeutics||N/A||-$14.85 million||-2.30|
|Pain Therapeutics Competitors||$284.28 million||$34.29 million||76.13|
Pain Therapeutics’ rivals have higher revenue and earnings than Pain Therapeutics. Pain Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a summary of recent ratings for Pain Therapeutics and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Pain Therapeutics Competitors||857||3201||11603||231||2.71|
As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.89%. Given Pain Therapeutics’ rivals stronger consensus rating and higher possible upside, analysts clearly believe Pain Therapeutics has less favorable growth aspects than its rivals.
This table compares Pain Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Pain Therapeutics Competitors||-5,312.21%||-433.82%||-39.43%|
Volatility & Risk
Pain Therapeutics has a beta of 2.12, suggesting that its share price is 112% more volatile than the S&P 500. Comparatively, Pain Therapeutics’ rivals have a beta of 8.49, suggesting that their average share price is 749% more volatile than the S&P 500.
Pain Therapeutics rivals beat Pain Therapeutics on 9 of the 12 factors compared.
Pain Therapeutics Company Profile
Pain Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK. REMOXY is a painkiller with a formulation designed to reduce potential risks of unintended use. The Company has developed REMOXY to make oxycodone difficult to abuse yet provide approximately 12 hours of steady pain relief when used by patients. REMOXY is intended to meet the needs of healthcare prescribing opioid drugs and seeking to minimize the risks of drug diversion, abuse or accidental patient misuse. The Company’s drug candidate FENROCK is an abuse-deterrent transdermal pain patch in the pre-Investigational new drug-stage of development. FENROCK is designed to provide pain relief over 72 hours.
Receive News & Ratings for Pain Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.